Castle Biosciences says ACG 2026 data show TissueCypher flags Barrett’s progression risk beyond biopsy findings

Castle Biosciences announced new TissueCypher data in Barrett’s esophagus scheduled for presentation at the ACG 2026 meeting in Nashville. Across two case reports and a multi-center study, the test flagged higher progression risk than biopsy findings suggested, prompting earlier escalation of care. Clinicians changed surveillance or treatment plans in most tested patients, supporting more individualized management beyond clinicopathologic risk tools. The studies also showed the test helped resolve conflicting pathology assessments, leading to earlier intervention and confirmation of more advanced disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via (Ref. ID: 202610121630PR_NEWS_USPR_____DA70022) on October 12, 2026, and is solely responsible for the information contained therein. (C)